Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Total Current Liabilities (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Total Current Liabilities for 4 consecutive years, with $132.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities rose 54.03% to $132.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $132.0 million, a 54.03% increase, with the full-year FY2025 number at $132.0 million, up 54.03% from a year prior.
  • Total Current Liabilities was $132.0 million for Q4 2025 at Phathom Pharmaceuticals, up from $93.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $132.0 million in Q4 2025 to a low of $11.4 million in Q1 2022.
  • A 4-year average of $50.8 million and a median of $41.1 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: grew 2.23% in 2023, then surged 200.9% in 2024.
  • Phathom Pharmaceuticals' Total Current Liabilities stood at $26.2 million in 2022, then skyrocketed by 47.81% to $38.8 million in 2023, then skyrocketed by 121.06% to $85.7 million in 2024, then soared by 54.03% to $132.0 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Total Current Liabilities are $132.0 million (Q4 2025), $93.1 million (Q3 2025), and $91.8 million (Q2 2025).